The stock's rise snapped a five-day losing streak.

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

Health Canada approved Pfizer-BioNTech’s updated COVID-19 vaccine on Tuesday, marking its third authorization of vaccine ...

We recently compiled a list of the 8 Best Wide Moat Stocks to Buy According to Analysts. In this article, we are going to ...

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks ...

Pfizer's stock underperformed its healthcare peers since PFE topped out in late July 2024. Click here to find out why I ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Pharmaceutical giant Pfizer ( PFE 2.73%) stands out in this context. The company currently offers a mouthwatering 5.7% ...

Pfizer is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug ...

A drug that could reduce the risk of death in cancer patients is showing good promise during its second phase of clinical ...

Jefferies analyst Akash Tewari maintained a Buy rating on Pfizer (PFE – Research Report) today and set a price target of $35.00. The ...

BioNTech's updated COVID-19 vaccine on Tuesday, marking its third authorization of vaccine formulations that protect against ...